J&J Medical Connect
INVEGA SUSTENNA®

(paliperidone palmitate)

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

INVEGA SUSTENNA - Dosing - Initiation

Last updated : 11/11/2024

SPECIFIC RESPONSE

Image Image Image
  • The initiation regimen for INVEGA SUSTENNA was designed to rapidly attain steady-state paliperidone concentrations when initiating therapy without the use of oral antipsychotic supplementation.
  • To avoid a missed dose, patients may be given the second initiation dose 4 days before or after the one-week time point.
  • Five weeks following the first initiation dose and monthly thereafter (± 1 week), maintenance doses can be administered in either the deltoid or gluteal muscle for sustained plasma levels up to one month.

aTo help attain therapeutic concentrations rapidly

BMI, body mass index; ER, extended release; IM, intramuscular; PK, pharmacokinetic.

References

Show Hide

1. INVEGA SUSTENNA [(paliperidone palmitate) Extended-Release Injectable Suspension] [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-54c7ff1c-5e50-4845-a605-24e8c5104cd7.